scispace - formally typeset
H

Henri A Ménard

Researcher at McGill University Health Centre

Publications -  16
Citations -  14091

Henri A Ménard is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Vimentin & Antigen. The author has an hindex of 10, co-authored 15 publications receiving 11807 citations. Previous affiliations of Henri A Ménard include McGill University.

Papers
More filters
Journal ArticleDOI

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI

Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

TL;DR: Citrullinated vimentin is an interesting candidate autoantigen in RA and may provide new insights into the potential role of citrullination synovial antigens and the antibodies directed to them in the pathophysiology of RA.
Journal ArticleDOI

Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities

TL;DR: This report shows for the first time that anti-CCP antibodies recognise multiple citrullinated proteins and are thus a collection of ACPA, as distinct non-crossreactive responses can also be detected in patients with RA.
Journal ArticleDOI

Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis

TL;DR: It is concluded that assays for antibodies against citrullinated antigens differ in their ability to predict poorer outcomes in patients with EPA, and detection of anti-Sa but not of RF or anti-CCP antibodies, in combination with clinical and radiological variables present at the first encounter allowed the identification of a subgroup of EPA patients suffering more rapid and more severe joint damage over 30 months.